Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
86.13
+0.65 (0.76%)
At close: Apr 9, 2026, 4:00 PM EDT
85.44
-0.69 (-0.80%)
After-hours: Apr 9, 2026, 6:36 PM EDT
Rhythm Pharmaceuticals Revenue
In the year 2025, Rhythm Pharmaceuticals had annual revenue of $189.76M with 45.83% growth. Rhythm Pharmaceuticals had revenue of $57.25M in the quarter ending December 31, 2025, with 36.87% growth.
Revenue (ttm)
$189.76M
Revenue Growth
+45.83%
P/S Ratio
30.99
Revenue / Employee
$458,350
Employees
414
Market Cap
5.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 189.76M | 59.63M | 45.83% |
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| Centessa Pharmaceuticals | 15.00M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 4.04M |
RYTM News
- 19 hours ago - Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - GlobeNewsWire
- 6 days ago - Rhythm Pharmaceuticals Announces Changes to Board of Directors - GlobeNewsWire
- 14 days ago - Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment - GlobeNewsWire
- 20 days ago - PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - PRNewsWire
- 21 days ago - Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 24 days ago - Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial - Reuters
- 24 days ago - Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity - GlobeNewsWire